Chiglitazar Added to Metformin for Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 533 participants.

Also called NCT04807348

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 533 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04807348
Other papers using this trial's data
  • Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS) Science bulletin, 2021-08-15 DOI, PubMed 36654287
  • Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study) Diabetes, obesity & metabolism, 2025-11 DOI, PubMed 40842343
  • Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP) Science bulletin, 2021-08-15 DOI, PubMed 36654286

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04807348. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-06 (actual); primary completion 2023-02-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Chiglitazar Added to Metformin for Type 2 Diabetes
Intervention (Drug)
Chiglitazar 32mg
Intervention (Drug)
Chiglitazar 48mg
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin Hydrochloride
Lead sponsor
Chipscreen Biosciences, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04807348
Content hash
77556d3facd940aceb2c02fe049835b18e543ecc229c3fc5408bd1cd0242e04f